Transplacental Pharmacokinetic Model of Digoxin Based on Ex Vivo Human Placental Perfusion Study

Ken Kurowsawa, Saki Noguchi, Tomohiro Nishimura, Masatoshi Tomi, and Koji Chiba

Department of Japan-Clinical Pharmacology and Pharmacometrics, Janssen Pharmaceutical K.K., Tokyo, Japan (K.K.); Laboratory of Clinical Pharmacology, Yokohama University of Pharmacy, Kanagawa, Japan (K.C.); and Faculty of Pharmacy, Keio University of Pharmacy, Tokyo, Japan (K.K., S.N., T.N., M.T.)

Received August 26, 2021; accepted December 10, 2021

ABSTRACT

Digoxin is used as first-line therapy to treat fetal supraventricular tachycardia; however, because of the narrow therapeutic window, it is essential to estimate digoxin exposure in the fetus. The data from ex vivo human placental perfusion study are used to predict in vivo fetal exposure noninvasively, but the ex vivo fetal-to-maternal concentration (F:M) ratios observed in digoxin perfusion studies were much lower than those in vivo. In the present study, we developed a human transplacental pharmacokinetic model of digoxin using previously reported ex vivo human placental perfusion data. The model consists of maternal intervillous, fetal capillary, non-perfused tissue, and syncytiotrophoblast compartments, with multidrug resistance protein 1 (MDR1) and influx transporter at the microvillous membrane (MVM) and influx and efflux transporters at the basal plasma membrane (BM). The model-predicted F:M ratio was 0.66, which is consistent with the mean in vivo value of 0.77 (95% confidence interval: 0.64-0.91). The time to achieve the steady state from the ex vivo perfusion study was estimated as 1,500 minutes, which is considerably longer than the reported ex vivo experimental durations, and this difference is considered to account for the inconsistency between ex vivo and in vivo F:M ratios. Reported digoxin concentrations in a drug-drug interaction study with MDR1 inhibitors quinine and verapamil were consistent with the profiles simulated by our model incorporating inhibition of efflux transporter at the BM in addition to MVM. Our modeling and simulation approach should be a powerful tool to predict fetal exposure and DDIs in human placenta.

SIGNIFICANCE STATEMENT

We developed a human transplacental pharmacokinetic model of digoxin based on ex vivo human placental perfusion studies in order to resolve inconsistencies between reported ex vivo and in vivo fetal-to-maternal concentration ratios. The model successfully predicted the in vivo fetal exposure to digoxin and the drug-drug interactions of digoxin and P-glycoprotein/multidrug resistance protein 1 inhibitors in human placenta.

Introduction

Digoxin is a cardiac glycoside extracted from the leaves of Digitalis lanata (Tantivatana and Wright, 1958). It has been used for many years to treat heart disease (Ziff et al., 2015), but therapeutic drug monitoring is recommended because of serious adverse effects resulting from even small exposure changes (Beller et al., 1971; Ragab, 2012). In obstetrics, transplacental treatment of pregnant women with digoxin has been used to manage fetal supraventricular tachycardia as first-line therapy (Strzelecka et al., 2017; Miyoshi et al., 2019). When digoxin is administered to pregnant women, dose escalation is recommended because pregnancy alters the drug disposition toward lower levels (Martin-Suarez et al., 2017), but it remains challenging to maximize the fetal efficacy of digoxin while minimizing the maternal adverse effects (Malham et al., 2019). Thus, it is crucial to predict in vivo fetal exposure of digoxin based on its transfer characteristics across the human placenta.

Ex vivo human placental perfusion study is a valuable tool to predict in vivo fetal exposure (Myren et al., 2007). Hutson et al. (2011) proposed a method to predict the in vivo fetal to maternal concentration (F:M) ratio from ex vivo data. Their predicted F:M ratios for twenty-four drugs were generally consistent with the in vivo F:M ratios, with the exception of four drugs. Digoxin was one of the exceptions, with a predicted F:M ratio much lower than the in vivo ratio. Hutson et al. (2011) suggested that the inconsistency between in vivo and ex vivo F:M ratios might be associated with efflux transport via multidrug resistance protein 1 (MDR1/P-glycoprotein/ABCB1) expressed at the microvillus plasma membrane (MVM) of human placental syncytiotrophoblasts (Ushigome et al., 2003; Ceckova-Novotna et al., 2006). Indeed, digoxin is a typical substrate of MDR1 (Tanigawara et al., 1992; Troutman and Thakker, 2003), and MDR1 inhibitors were reported to alter digoxin uptake by MVM vesicles obtained from normal human term placenta (Ushigome et al., 2003). However, an ex vivo human placental perfusion study failed to find a significant effect of MDR1 inhibitors, such as quinidine and verapamil, on the transplacental transfer of digoxin (Holberg et al., 2003), although ex vivo perfusion studies have successfully demonstrated the involvement of placent MDR1 in suppressing fetal transfer and drug-drug interactions (DDIs) of drugs, such as indinavir, vinblastine (Sudhakaran et al., 2008), lopinavir (Ceccaldi et al., 2009), methadone, paclitaxel (Nanovskaya et al., 2005), and methadone (Novotna et al., 2006). Indeed, digoxin is a typical substrate of MDR1 (Tanigawara et al., 1992; Troutman and Thakker, 2003), and MDR1 inhibitors were reported to alter digoxin uptake by MVM vesicles obtained from normal human term placenta (Ushigome et al., 2003). However, an ex vivo human placental perfusion study failed to find a significant effect of MDR1 inhibitors, such as quinidine and verapamil, on the transplacental transfer of digoxin (Holberg et al., 2003), although ex vivo perfusion studies have successfully demonstrated the involvement of placent MDR1 in suppressing fetal transfer and drug-drug interactions (DDIs) of drugs, such as indinavir, vinblastine (Sudhakaran et al., 2008), lopinavir (Ceccaldi et al., 2009), methadone, paclitaxel (Nanovskaya et al., 2005), and methadone (Novotna et al., 2006).
and saquinavir (Mõlsä et al., 2005). Accordingly, quantitative assessment of the interaction of digoxin with MDR1 inhibitors is needed to determine the contribution of MDR1 to the suppression of fetal digoxin transfer and to understand the reason for the inconsistency between in vivo and ex vivo studies.

A human transplacental pharmacokinetic (PK) model incorporating parameters of passive and active (transporter-mediated) transmembrane transfers estimated from ex vivo human placenta perfusion studies can generate quantitative insights into the mechanisms governing the fetal transfer of drugs (Kurosawa et al., 2020). Therefore, the purpose of this present study was to develop a human transplacental PK model of digoxin to predict in vivo fetal exposure to digoxin and digoxin DDIs at MDR1 in the human placenta.

Materials and Methods

A schematic diagram illustrating the development of the transplacental PK model to predict DDIs of digoxin in the human placenta and in vivo fetal exposure to digoxin is shown in Fig. 1. The procedure consisted of the following four steps: i) model construction, ii) verification of the model for different experimental conditions, iii) prediction of DDIs of digoxin and MDR1 inhibitors, and iv) confirmation for in vivo fetal exposure. In the first step, the model was constructed by fitting to reported digoxin concentration-time profiles obtained in an ex vivo human placental perfusion study with a closed system (Derewlany et al., 1991). Next, verification was conducted by applying the model to data obtained under different experimental conditions (Holcberg et al., 2003).

Fig. 1. Schematic illustration of the development of the digoxin transplacental pharmacokinetics model. i) Model construction. ii) Model verification. iii) Prediction of drug-drug interactions of digoxin and multidrug resistance protein 1 inhibitors. iv) Prediction of in vivo fetal exposure.

Development of the Transplacental PK Model of Digoxin.

The digoxin transplacental PK model (Fig. 2A) was constructed based on our previous model for metformin (Kurosawa et al., 2020), with the modification of adding a non-perfused placental tissue compartment (Fig. 2, A and B). In a typical human placental perfusion experiment using a single cotyledon, non-perfused regions, which are parts of cotyledon adjacent to the perfused single cotyledon (Fig. 2B), remain (Mathiesen et al., 2010; Grafmüller et al., 2013). In the reported perfusion study (Derewlany et al., 1991), the digoxin concentrations and weights of the non-perfused cotyledon and the non-perfused tissue were measured following the perfusion. Therefore, the non-perfused tissue compartment was incorporated into the transplacental PK model separately from the maternal placental compartment (Fig. 2A).

As observed for fitting, we obtained the time and the digoxin concentrations in maternal artery, maternal vein, umbilical artery, umbilical vein, perfused placental tissue (syncytiotrophoblast), and non-perfused placental tissue from the tables and figures published in the report of the ex vivo human placental perfusion study (Derewlany et al., 1991) using WebPlotDigitizer Version 4.4 (https://automeris.io/WebPlotDigitizer). In that study, a closed perfusion system was applied to a single cotyledon subdivided from the normal-term human placenta at delivery. The medium was perfused at flow rates of Qm for the maternal circuit and Qf for the fetal circuit (Table 1). Digoxin (Lanoxin®) at the initial concentration of 5.5 ng/mL (digitized from the reported figure) in the maternal reservoir was recirculated in the maternal and fetal circuits for 180 minutes. The differential equations of the digoxin transplacental PK model are as follows (Eqs. 1-10):

\[ V_m \times \frac{dC_m}{dt} = Q_m \times (C_m - C_{m}) \] (1)

\[ V_m \times \frac{dC_{ma}}{dt} = Q_{ma} \times (C_{ma} - C_{ma}) \] (2)

\[ V_{ma} \times \frac{dC_{ma}}{dt} = (C_{ma} - C_{ma}) \times Q_m + (PS_{MVM,act,eff} + PS_{MVM,inf}) \times f_{a,act} \times C_i - (PS_{MVM,act,inf} + PS_{MVM,inf}) \times f_{a,med} \times C_{ma} - Q_{ma} \times (f_{a,med} \times C_{ma} - f_{a,med} \times C_{ma}) \] (3)

\[ V_m \times \frac{dC_{mc}}{dt} = Q_m \times (C_{mc} - C_{mc}) \] (4)

\[ V_{mc} \times \frac{dC_{mc}}{dt} = (PS_{MVM,act,inf} + PS_{MVM,inf}) \times f_{a,med} \times C_{mc} + (PS_{BM,act,inf} + PS_{BM,inf}) \times f_{a,act} \times C_i - (PS_{BM,act,inf} + PS_{BM,inf}) \times f_{a,med} \times C_{mc} \] (5)

\[ V_{mc} \times \frac{dC_{mp}}{dt} = Q_{mp} \times (f_{a,med} \times C_{mp} - f_{a,med} \times C_{mp}) \] (6)

\[ V_f \times \frac{dC_f}{dt} = Q_f \times (C_f - C_f) + (PS_{BM,act,eff} + PS_{BM,inf}) \times f_{a,act} \times C_i - (PS_{BM,act,inf} + PS_{BM,inf}) \times f_{a,med} \times C_f \] (7)

\[ V_m \times \frac{dC_{mf}}{dt} = Q_{mf} \times (C_{mf} - C_{mf}) \] (8)

\[ V_f \times \frac{dC_{mf}}{dt} = Q_f \times (C_{mf} - C_{mf}) \] (9)

\[ V_m \times \frac{dC_{mu}}{dt} = Q_{mu} \times (C_{mu} - C_{mu}) \] (10)
where $C_{mr}$, $C_{ma}$, $C_{mp}$, $C_{mv}$, $C_{t}$, $C_{np}$, $C_{fc}$, $C_{uv}$, and $C_{ua}$ represent the total digoxin concentrations in the maternal reservoir ($C_{mr}$), maternal artery ($C_{ma}$), maternal placenta ($C_{mp}$), maternal vein ($C_{mv}$), syncytiotrophoblast ($C_{t}$), non-perfused placental tissue ($C_{np}$), fetal capillary ($C_{fc}$), umbilical vein ($C_{uv}$), and umbilical artery ($C_{ua}$) compartments. At time 0 minutes (the start of digoxin perfusion), $C_{mr}$ was 5.5 ng/ml, and other parameters were fixed on ng/ml. $V_{mr}$, $V_{ma}$, $V_{mp}$, $V_{mv}$, $V_{t}$, $V_{np}$, $V_{fc}$, $V_{uv}$, and $V_{ua}$ are the volumes of the maternal reservoir ($V_{mr}$), sampling port of the maternal artery ($V_{ma}$), maternal placenta ($V_{mp}$), maternal vein ($V_{mv}$), syncytiotrophoblast ($V_{t}$), non-perfused placental tissue ($V_{np}$), fetal capillary ($V_{fc}$), sampling port of the umbilical vein ($V_{uv}$), and fetal reservoir ($V_{ua}$). $V_{mr}$ is the sum of the volume of the perfusion medium in the maternal chamber ($V_{ch}$) and maternal intervillous volume ($V_{mi}$) (Kurosawa et al., 2020). $f_{u,med}$, $f_{u,np}$, and $f_{u,t}$ denote the unbound fractions of digoxin in the medium of maternal and fetal circuits ($f_{u,med}$), the non-perfused placental tissue ($f_{u,np}$), and the syncytiotrophoblast ($f_{u,t}$). $Q_{np}$ is the intercompartmental clearance between the maternal placenta and non-perfused placental tissue.

The passive clearances of digoxin in the MVM (PSMVM,diff) and the basal plasma membrane (BM, PSBM,diff) were calculated using the same method as that in our previous report (Kurosawa et al., 2020). The calculations are described in detail in Supplemental Text and Supplemental Table 1. Because digoxin is not extensively metabolized, no metabolic clearance was assumed in...
PSMVM, act, eff, respectively) and BM (PSBM, act, infand PSBM, act, eff, respectively) were assumed to be the same as fu,t.

The calculation method of fu,t is described in the Supplemental Text. Vfa,V mi, and Vt are expressed as volume of a single cotyledon unit in human placenta.

The estimation method of fu,med is described in the Supplemental Text.

The calculation method of perfused tissue volumes (Vfc,V mi, andVt) is described in the Supplemental Text. Vfc,V mi, and Vt are expressed as volume of a single cotyledon unit in human placenta.

The model fitting was performed using NONMEM version 7.4 (Icon Development Solutions, Ellicott City, MD, USA; Beal and Sheiner, 1989) with nonlinear least-squares regression. The R Project for Statistical Computing, Version 3.5.2 for Windows (Comprehensive R Network, http://cran.r-project.org) was used for the graphics generation, post-processing of NONMEM, and statistical analysis.

**Verification of the Human Transplacental PK Model for Digoxin.** The transplacental PK model constructed by using the data of Derewłany et al. (1991) was applied to other ex vivo perfusion studies in different experimental settings, reported by Holcberg et al. (2003). The simulation of Cma and Cuv was performed using the same model. The physicochemical properties of digoxin, the physiologic parameters of human placental cotyledon, and the experimental conditions used for the model verification are listed in Supplemental Table 2.

**Model Prediction of DDIs between Digoxin and MDR1 Inhibitors.** Digoxin is a substrate of MDR1 (Fenner et al., 2009) at the MVM (Ushigome et al., 2003; Ceckova-Novotna et al., 2006) and is transported from syncytiotrophoblast at the maternal side (Nekhayeva et al., 2006; Sudhakaran et al., 2008). Holcberg et al. (2003) examined the DDIs of digoxin with MDR1 inhibitors quinidine and verapamil, even though no inhibition was observed in the perfusion studies. To quantitatively assess the DDIs of digoxin and these inhibitors, simulations were performed using the developed transplacental PK model of digoxin with the following equation (Eq. (11))

$$P_{S_{MVM, act, eff}(+inhibitor)} = \frac{PS_{SVM, act, eff}}{1 + \frac{[I]}{K_{I,MVM}}}$$

where I and K_{I,MVM} represent the total inhibitor concentration in syncytiotrophoblast and the inhibition constant for MDR1 at the MVM, respectively. For K_{I,MVM, VRP}, the values obtained in in vitro studies (Chauldry et al., 2018) were used (Supplemental Table 2).

It was assumed that quinidine and verapamil were not metabolized in the ex vivo human placental perfusion studies. Quinidine is mainly metabolized by cytochrome P450 (CYP) 3A4 (Nielsen et al., 1999) and verapamil by CYP3A4/5 and CYP2C8 (Tracy et al., 1999). However, messenger ribonucleic acid and protein expression levels of these enzymes are low or undetectable in human placenta (Hakkola et al., 1996; Bieche et al., 2007). Thus, no metabolic clearance was incorporated in the present model of quinidine, and this was also assumed to be the case for verapamil in the DDI simulation studies.

The transplacental PK model of quinidine (Fig. 2A) was constructed using the quinidine concentrations in the maternal artery, umbilical vein, and syncytiotrophoblast taken from the previously reported ex vivo human placental perfusion study (https://primo.bgu.ac.il/permalink/t14jqpxc972BGU_ALMA51118865170)
In that study, a closed perfusion system was applied to a single cotyledon obtained from a normal-term human placenta at delivery. The experimental settings for the quinidine transplacental PK model are summarized in Supplemental Table 3. The $PS_{MVM,\text{test}}$ and $PS_{B,\text{test}}$ of quinidine were calculated using the same method as employed for the digoxin model (Supplemental Text). $PS_{MVM,\text{act}}$, $PS_{B,\text{act}}$, $PS_{B,\text{act,eff}}$ and $PS_{B,\text{act,eff}}$ were also assumed to influence the active transport of quinidine in the human placenta in the model construction. The same data collection methods and model fitting as in the case of digoxin were used for the quinidine model development.

As for verapamil, the initial concentration of 250 ng/mL in the maternal circuit was assumed to be maintained throughout the DDI study. $I_v$ of verapamil was calculated using the syncytiotrophoblast to maternal reservoir concentration ratio of 0.97, obtained in a macaque study (Iyal et al., 2009), as the interhemal barrier of the rhesus monkey is considered analogous to that of humans (Panigel et al., 1975; Grigsby, 2016). A sensitivity analysis showed that syncytiotrophoblast to maternal reservoir concentration ratio values between 0.3 and 3 had almost no effect on the digoxin PK profile in the DDI study (data not shown).

The physicochemical properties of quinidine and verapamil, the physiologic parameters of human placental cotyledon, and the experimental conditions used for the DDI predictions of digoxin with quinidine or verapamil are summarized in Supplemental Table 2.

**Model Prediction of In Vivo Fetal Digoxin Exposure.** To predict in vivo fetal exposure to digoxin, $C_{ma}$ and $C_{uv}$ at the steady state were simulated by the developed transplacental PK model for the experimental conditions used in the ex vivo perfusion study by Derewlany et al. (1991). For the in vivo prediction, the $f_{\text{med}} (=0.67$ for mother and fetus) of digoxin in humans under physiologic conditions (Hubert et al., 1985; Hebert et al., 2008) was used. To predict in vivo $F:M$ ratio, it is hypothesized that $F:M$ ratio obtained from a single cotyledon corresponds to that of whole placenta consisting of approximately 15–30 cotyledons (Gundalli et al., 2015). Then, the ratios of the simulated steady-state $C_{ma}$ and $C_{uv}$ values were used as the predicted in vivo $F:M$ ratios. The predicted in vivo $F:M$ ratios were compared with the in vivo $F:M$ ratio integrated from multiple clinical reports (Rogers et al., 1972; Chen et al., 1978; Nagashima et al., 1986; Zhou et al., 2011) using the Dersimonian and Laird method (Dersimonian and Laird, 1986). The clinical information from the multiple reports of in vivo $F:M$ ratios are summarized in Supplemental Table 4.

To predict in vivo fetal exposures to digoxin in the presence of the MDR1 inhibitors quinidine and verapamil, the increase in maternal concentration of digoxin caused by inhibiting MDR1 in the small intestine and kidney as well as placenta should be considered. Therefore, the maximum concentrations ($C_{\text{max}}$) of drugs after oral administration of digoxin with/without quinidine at the therapeutic dosage to cardiac patients or verapamil (240 mg/d) to healthy volunteers in clinical DDI studies (Pedersen et al., 1983; Rodin et al., 1988) (listed in Supplemental Table 5) were also applied to the simulation of digoxin transplacental PK profiles using the developed model.

**Results**

**Development of Digoxin Human Transplacental PK Model.** The human transplacental PK model for digoxin was developed using reported data obtained in a closed perfusion system of human placenta, which includes non-perfused tissue (Derewlany et al., 1991). The fitted profiles of digoxin concentration-time profiles for $C_{ma}$, $C_{mv}$, $C_{uv}$, $C_{uv}$, $C_{np}$ and $C_{np}$ are shown in Fig. 3, A-C. The transplacental PK model well captured the observed concentrations of digoxin in the ex vivo study. The estimated parameters are listed in Table 1. $V_{ch}$ was estimated as 49.6 mL, which is consistent with the actual measured weight of non-perfused tissue (44.2 g) reported by Derewlany et al. (1991).

**Verification of the Digoxin Human Transplacental PK Model.** The values of digoxin $C_{ma}$ and $C_{uv}$ previously obtained in an ex vivo closed perfusion experiment (Holcberg et al., 2003) were used to examine whether the developed transplacental model (Fig. 2A) is applicable to different ex vivo perfusion conditions. The observed $C_{ma}$ and $C_{uv}$ were well simulated by the developed model (Fig. 4).

The value of 11.5 mL for $V_{ch}$, which was estimated by fitting to the quinidine concentrations in the reported perfusion study (https://primo.bgu.ac.il/permalink/f/14tjq6c/972BGU_ALMA51118865170004361) as described below (“Application of the developed model to ex vivo DDI studies”) was used in the digoxin PK simulations of the digoxin perfusion and DDI studies (Holcberg et al., 2003). Because the $V_{ch}$
values may be different among perfusion studies, sensitivity analysis of $V_{ch}$ was performed. Holcberg et al. (2003) stated that the remaining medium in the chamber was kept at the lowest level on part of the placenta (42.66 g), which consisted of perfused cotyledon and non-perfused tissue. Therefore, in the sensitivity analysis, the lower and upper limit values of $V_{ch}$ were set at 0 (no remaining medium) and 50 mL, respectively. The simulated values of $C_{ma}$ and $C_{uv}$ were well overlapped with the observed values in the digoxin perfusion study by Holcberg et al. (2003) (Fig. 4). Thus, the influence of variation of $V_{ch}$ can be neglected.

**Application of the Developed Model to Ex Vivo DDI Studies.**

The profiles simulated by the model incorporating influx and efflux transporters on both the MVM and BM were consistent with the reported digoxin concentration profiles. Therefore, the possibility of inhibition of these transporters by co-administered drugs, especially MDR1 inhibitors, should be considered. However, Holcberg et al. (2003) observed no inhibition by quinidine or verapamil in an ex vivo placental DDI study of digoxin with the MDR1 inhibitors quinidine and verapamil in their ex vivo human placental perfusion system, which afforded the data used to verify our developed transplacental PK model for digoxin perfusion without inhibitors. To consider the reasons for this negligible inhibitory effect, we applied our model to the reported DDI study of digoxin and verapamil since sufficient data were not available to construct a human placental PK model. Specifically, to avoid a false-negative prediction of DDI, it was assumed that the unbound syncytiotrophoblast concentration of verapamil of 41.2 ng/mL, calculated from the maximum (initial) concentration of verapamil in the maternal circuit (250 ng/mL), was maintained statically (static model).

Since MDR1 is present at the MVM (Ushigome et al., 2003; Ceckova-Novotna et al., 2006), the efflux transporter of digoxin at the MVM is most likely MDR1. Therefore, simulations were performed with inhibition of MDR1 at the MVM by quinidine and verapamil based on the reported $K_{M,MDR1,MVM}$ of 0.27 and $K_{M,MDR1,MVM}$ of 0.55 μM, respectively (Chaudhry et al., 2018). Furthermore, the efflux transporter of digoxin at the BM could also be sensitive to quinidine and verapamil, since MDR1 and/or MDR3, both of which accept digoxin as a substrate (Smith et al., 2000) and are sensitive to quinidine and verapamil (Schlemmer and Sirotnak, 1994; Aleo et al., 2017), are expressed at the BM of syncytiotrophoblasts and/or cytotrophoblast, adjacent to the BM of the syncytiotrophoblast (Evesencko et al., 2006, 2007; Lye et al., 2013; Kliman et al., 2018). Therefore, the simulations were performed in the presence and absence of inhibition of the efflux transporter at the BM by quinidine and verapamil, as shown in Fig. 5. Various $K_i$ values for the efflux transporter at the BM were set: 0.027 μM (green lines), 0.27 μM (blue lines), and 2.7 μM (purple lines) for quinidine ($K_{i,BM,MVM}$) and 0.055 μM (green lines), 0.55 μM (blue lines), and 5.5 μM (purple lines) for verapamil ($K_{i,BM,VRP}$), in addition to the case that BM transporters were insensitive to these drugs (orange lines). These values were chosen for sensitivity analyses because the kinetic parameters of the efflux transporter at the BM are unknown. In the case of quinidine inhibition, the observed digoxin concentrations in the presence of quinidine were close to the simulated concentrations of digoxin with the lower $K_{i,BM,MVM}$ values of 0.027 and 0.27 μM (Fig. 5A). In the case of verapamil inhibition, the simulated digoxin concentrations overlapped the observed concentrations in the presence of verapamil, except at the lowest $K_{i,BM,VRP}$ (0.055 μM) (Fig. 5B).

Since the steady state of digoxin was not achieved at the reported perfusion time of 120 minutes, simulations of longer-term perfusions in the presence and absence of quinidine or verapamil were carried out (Supplemental Fig. 2, A and B). For quinidine, the unbound syncytiotrophoblast concentration of quinidine at the steady state was estimated as 1.22 μg/mL, which is higher than $K_{i,MDR1,MVM}$ and $K_{i,BM,MVM}$ (Supplemental Fig. 2C). Indeed, the simulation profiles in the case of longer-term perfusion (5,000 minutes, Supplemental Fig. 2A) were different in the presence and absence of quinidine. The co-administration of quinidine decreased the fetal transfer of digoxin if the efflux transporter at the BM showed higher affinity (Fig. 5A). However, the transfer of digoxin at the BM was insensitive or had the lowest affinity ($K_{i,BM,VRP}$) (Fig. 5B).

### Model Prediction for In Vivo Human F:M Ratio of Digoxin.

In the ex vivo experiment (Derewlany et al., 1991), a lower albumin concentration (Table 1) than that in vivo was used, and the perfusion of digoxin was terminated at 180 minutes. When the digoxin $C_{ma}$ and $C_{uv}$ were simulated with a higher albumin concentration reflecting the in vivo value ($fu_{med} = 0.67$ for mother and fetus) and longer-term perfusion, the time to achieve the steady state ($t_{ss}$) was approximately 1,500 minutes (Fig. 6). The F:M ratio at the steady state in the in vivo...
condition was calculated as approximately 0.66, which is consistent with previously reported in vivo F:M ratios (mean 95% confidence interval (CI): 0.77 [0.64-0.91]) (Fig. 7).

Estimation of In Vivo F:M Ratio for DDIs between Digoxin and MDR1 Inhibitors. As described above, co-administration with quinidine might decrease the fetal transfer of digoxin based on the results of ex vivo DDI simulations for long-term perfusion. In clinical settings, the increase of maternal digoxin exposure due to inhibition of MDR1 in the small intestine and kidney should also be considered. It is reported that quinidine increases the digoxin exposure, i.e., Cmax and the area under the plasma concentration-time curve, by approximately 1.8-fold, while verapamil increases it by approximately 1.4-fold after digoxin oral administration with quinidine or verapamil, respectively (Pedersen et al., 1983; Rodin et al., 1988). Therefore, the maternal and fetal exposures to digoxin were simulated using the reported clinical Cmax of digoxin after co-administration with quinidine or verapamil as an initial Cmr (Pedersen et al., 1983; Rodin et al., 1988) by the developed transplacental PK model, and the results were compared with the simulation using data in the absence of the MDR1 inhibitor (Supplemental Table 5). In parallel, the developed transplacental PK model for quinidine was used with its reported clinical Cmax as an initial Cmr with no inhibition by quinidine at the basal plasma membrane (orange). Black closed circles and triangles represent the reported mean concentrations of digoxin in maternal artery and umbilical vein. The red lines represent the simulated digoxin-concentration time profiles in maternal artery (solid) and umbilical vein (dashed) without multidrug resistance protein inhibitors. The lines in B, except for green lines, almost overlapped and are visually indistinguishable. Quinidine or verapamil was added to the maternal reservoir at 7.57 μg/ml or 250 ng/ml, respectively. The medium without digoxin but including an multidrug resistance protein 1 inhibitor was perfused for 45 min prior to start of digoxin perfusion. After the pre-perfusion period, digoxin (6.07 ng/ml at 0 min in A, 5.22 ng/ml at 0 min in B) was added to the maternal reservoir in the experiments. Digoxin concentrations in B were normalized by the initial maternal concentration observed in A (6.07 ng/ml).

The observed digoxin concentrations in ex vivo DDI perfusion experiments with quinidine were appropriately accounted for by the two simulations in which quinidine inhibited the efflux transporter at BM with Ki,MDR1,MVM,QND 0.027 and 0.27 μM and also inhibited MDR1 at the MVM with Ki,MDR1,MVM,MND 0.27 μM (Fig. 5A). Therefore, the maternal and fetal digoxin concentration profiles were simulated by the developed model by using these Ki values and the digoxin Cmax obtained from a clinical DDI study with quinidine (Pedersen et al., 1983) (Fig.
For verapamil, the three simulations in which the efflux transporter at the BM was sensitive to verapamil with $K_{\text{BM,VRP}}$ 0.55 and 5.5 $\mu$M or was insensitive, while verapamil inhibits MDR1 at the MVM with $K_{\text{MDR1,MM,VRP}}$ 0.55 $\mu$M, adequately accounted for the observed digoxin concentrations in the ex vivo DDI perfusion experiments (Fig. 5B). With these $K_i$ values and the digoxin $C_{\text{max}}$ reported in a clinical DDI study with verapamil (Rodin et al., 1988), the maternal and fetal digoxin concentration profiles were simulated by the developed model (Fig. 8B). As a result, the steady-state maternal and fetal digoxin concentrations in all simulations after co-administration of verapamil (blue, purple, and orange lines) were 1.4- to 1.5-fold higher than those in the absence of verapamil (red lines), which are almost the same as the increases in exposure observed in subjects who were not pregnant (Rodin et al., 1988). Therefore, the increments were mainly accounted for by MDR1 inhibition in maternal organs other than placenta due to the lower unbound verapamil concentration of 90.0 ng/mL (= 0.20 $\mu$M), compared with $K_{\text{MDR1,MM,VRP}}$ (0.55 $\mu$M) and $K_{\text{BM,VRP}}$ (0.55 and 5.5 $\mu$M) in syncytiotrophoblast (Fig. 8D). The F:M ratios of digoxin after co-administration of verapamil were estimated to be 0.65–0.74, which are almost the same as that in the absence of verapamil (0.66).

**Discussion**

Data from ex vivo human placental perfusion were used here to predict fetal drug exposure in vivo. A previous systematic review (Hutson et al., 2011) stated that ex vivo F:M ratios were generally consistent with the in vivo F:M ratios, although there were 4 exceptions among 24 drugs, i.e., digoxin, metformin, glyburide, and oxcarbazepine. Those four drugs are substrates of active transporters, and digoxin is a typical MDR1 substrate (Tanigawara et al., 1992; Kullak-Ublick et al., 2001; Sata et al., 2005; Han et al., 2015; Nakamichi et al., 2013; Gedeon et al., 2006; Zhang et al., 2011). The F:M ratio of digoxin predicted by Hutson et al. (2011) was approximately 7-fold lower than the previously reported in vivo F:M ratio. In the present study, our developed human transplacental PK model of digoxin successfully predicted an F:M ratio (0.66) comparable with the in vivo value (0.77). When digoxin is used for fetal supraventricular tachycardia, the concentration in the fetus should be adjusted to the therapeutic range with simultaneous adjustment of maternal exposure to avoid maternal digoxin toxicity. Thus, accurate prediction of the ratio is important for design of the dosing strategy.

Our analysis revealed that the reason for the discrepancy between in vivo and ex vivo F:M ratios of digoxin is that the estimated $t_{\text{ss}}$ is longer than the duration of perfusion in the previous ex vivo studies (Hutson et al., 2011). Recently, we reported a transplacental PK model of metformin (Kurosawa et al., 2020), another exception in Hutson’s systematic review. The ex vivo F:M ratios of metformin from closed perfusion studies were 2- to 5-fold lower than the in vivo values, and this inconsistency was explained by the longer $t_{\text{ss}}$ than the perfusion time in the ex vivo experimental settings, as in the present case of digoxin. Both digoxin and metformin are low-permeability compounds classified as biopharmaceutics classification system class 3 (Cheng et al., 2004; Xia et al., 2013), which should have permeability-limited kinetics. Therefore, digoxin and metformin would have long $t_{\text{ss}}$ (1,500 minutes and 1,000 minutes, respectively) in ex vivo perfusion studies. In the previous metformin model and the present digoxin PK model, influx and efflux clearances were set in the MVM and BM, respectively, and successfully accounted for the permeability-limited kinetics.
Fig. 8. The long-term transplacental transfer simulations of digoxin for predicting inhibitory effects of placental multidrug resistance protein 1 at the microvillus membrane and/or the efflux transporter at the basal plasma membrane by quinidine (A) and verapamil (B) on the basis that these inhibitors enhanced digoxin concentration in maternal reservoir after oral co-administration with digoxin by inhibiting multidrug resistance protein 1 in maternal organs other than placenta. The digoxin concentration-time profiles in maternal artery (solid lines) and umbilical vein (dashed lines) were simulated in the presence of quinidine (green and blue lines in A) or verapamil (blue, purple and orange lines in B) in a closed perfusion system (Holcberg et al., 2003). A: $K_i,_{\text{MDR1},\text{MVM},\text{QND}}$ was set as 0.27 $\mu$M and $K_i,_{\text{BM},\text{QND}}$ as 0.027 (green) or 0.27 $\mu$M (blue). B: $K_i,_{\text{MDR1},\text{MVM},\text{VRP}}$ was set as 0.55 $\mu$M and $K_i,_{\text{BM},\text{VRP}}$ as 0.55 (blue), or 5.5 $\mu$M (purple) with no inhibition by verapamil at the basal plasma membrane (orange). The red lines in A and B represent the simulated digoxin-concentration time profiles in maternal artery (solid) and umbilical vein (dashed).
In the previous transplacental PK model analysis of digoxin (Derewlany et al., 1991), a PK model consisting of maternal and fetoplacental compartments was applied to ex vivo human placental perfusion data to explain the digoxin concentration-time profile only on the maternal side. Since fetal concentrations were not used to build the model, the estimation of fetal exposure and comparison of ex vivo and in vivo data were not conducted. Moreover, since the syncytiotrophoblast compartment was not separated from the fetal compartment and transportation between placenta and fetus was not considered, it is difficult to simulate transporter-mediated DDI at the unbound drug concentration in syncytiotrophoblasts. On the other hand, our PK model shown in Fig. 2A successfully predicted the DDIs in human placenta by taking account of the possibility that the efflux transporter at the BM is inhibited by MDR1 inhibitors.

The present model incorporates four transporter-mediated clearances in the transplacental transfer of digoxin. When we compared the model-estimated active transport clearances of digoxin with the passive diffusion clearances obtained from parallel artificial membrane permeation assay, the active transport clearances were 2 to 7 times larger than the parallel artificial membrane permeation assay clearances (Table 1). Moreover, when the model fitting was performed with only four passive clearances, one solely passive and three hybrid clearances (passive + active clearances), two solely passive and two hybrid clearances, or three solely passive and one hybrid clearances, convergence failed in all cases (data not shown). Furthermore, sensitivity analyses for the four transporters were performed to investigate the influences of changes in the activities (Supplemental Fig. 3). As a result, the digoxin concentration profiles were sensitively shifted by each change in clearance, and the robustness of the model with the four estimated clearances were confirmed. These results clearly indicate that transporters are involved in the influx and efflux transport at the MVM and BM.

Among transporters expressed at the MVM of human placental syncytiotrophoblasts, the efflux transport of digoxin from the syncytiotrophoblasts to the maternal intervillous space by MDR1 has been functionally confirmed, since the uptake of digoxin into human placental MVM vesicles was decreased in the presence of MDR1 inhibitors, such as verapamil, progestosterone, and cycloporsine A (Ushigome et al., 2003). Organic anion transporting polypeptide (OATP) IB3 has been reported to transport digoxin in the human placenta (Tupova et al., 2020; Kullak-Ublick et al., 2001), but this remains controversial (Kimoto et al., 2011; Taub et al., 2011). Further investigation is necessary to evaluate digoxin transport by OATP1B3 in human placenta. At the BM, MDR3, and MDR1 at the cytotrophoblast adjacent to the syncytiotrophoblast could transport their substrates from syncytiotrophoblasts to fetus (Evseenko et al., 2006; Lye et al., 2013; Kliman et al., 2011), which is located at the MVM, MDR1 is likely to serve as the efflux transporter at the BM. The stronger inhibition of the efflux transporter at the BM results in lower fetal digoxin concentrations. On the other hand, for verapamil, the increments in fetal exposure were accounted for by the inhibition of MDR1 in the maternal intestine and kidney, but not in the placenta because of the lower unsynctiotrophoblast concentration of verapamil than K_{MVM,VRP} and K_{BM,VRP}. Thus, because of an increase in digoxin concentration in the mother even if the increase in fetal digoxin concentration is similar to or less than that of maternal concentration, therapeutic monitoring of digoxin should be considered to predict fetal exposure when these MDR1 inhibitors are co-administered with digoxin in vivo.

In this study, we also constructed the first human transplacental PK model of quinidine with transporter-mediated clearances. Transporters involved in the transplacental transfer of quinidine have not yet been clarified. However, since quinidine is a substrate of MDR1 (Patil et al., 2011), which is located at the MVM, MDR1 is likely to serve as the MVM efflux transporter. As for other transporters, when four passive diffusions or those with transporter clearances were tested, only the model fitting with MDR1 on MVM and an unknown efflux transporter on BM with four passive diffusions converged (data not shown). This model made it possible to estimate the MDR1-inhibitory effect of quinidine on digoxin transplacental transfer. Considering that quinidine is a substrate of organic cation transporter 3 (Hasannejad et al., 2004), which is expressed at the BM (Kekuda et al., 1998), organic cation transporter 3 may contribute to the transportation of quinidine in the placenta.

For the successful construction of the transplacental PK model from ex vivo perfusion studies, digoxin concentrations in non-perfused tissue as well as maternal artery, umbilical vein, perfused tissue, and the weight of perfused tissue are required. The volumes of maternal intervillous, syncytiotrophoblast and fetal capillaries can be calculated from reported values (Supplemental Text). On the other hand, it is difficult to measure the non-perfused tissue volume accurately because of

---

Fig. 8. (cont.) without the inhibitors. The lines in B, except for red lines, almost overlapped and are visually indistinguishable. The simulated quinidine and verapamil concentration-time profiles in syncytiotrophoblast (black solid) are presented in C and D, respectively. C: Green and blue represent K_{BM,VRP} of 0.027 and 0.27 μM, respectively. K_{MVM,VRP} overlapped with the blue line. D: Blue and purple lines represent K_{BM,VRP} of 0.55 and 5.5 μM, respectively. K_{MVM,VRP} overlapped with the blue line. The simulations by the developed transplacental pharmacokinetic model of digoxin followed Holcberg’s ex vivo studies except for enhanced maternal digoxin concentrations in the case of co-administration with inhibitor (Pedersen et al., 1983; Rodin et al., 1988) and f_{p,neo} in human plasma (Hubert et al., 1985; Mihaly et al., 1987; Belpaire et al., 1995; Hebert et al., 2008) (Supplemental Table 5).
unexpected spontaneous blood clotting and the vague boundary with unexpected spontaneous blood clotting and the vague boundary with


Address correspondence to: Dr. Koji Chiba, Laboratory of Clinical Pharmacology, Yokohama University of Pharmacy, 601 Matano-cho, Totsuka-ku, Yokohama-shi, Kanagawa 245-0066, Japan. E-mail: k.chiba@hamayaku.ac.jp